|
Post by mannmade on Sept 26, 2016 16:34:53 GMT -5
KC while I often agree with you why would Mnkd consider selling at 15 to 20 pps? That would have to mean substantive progress is being made on all fronts and there is more to come... Just my opinion...
|
|
|
Post by mannmade on Sept 25, 2016 21:28:04 GMT -5
Broadcast is very expensive and not very targeted for the most part. Let's be happy with a smart and targeted digital campaign. Seems like every time I open up an article for AFREZZA online lately I see an ad embedded for Trulicity or some other diabetes drug. How about if we start with AFREZZA ads like that? Would love to see an AFREZZA ad in an article about Toujeo... There is a reason TV ratings including cable are on the decline and it is because of digital, online and mobile... Not to say TV will never be appropriate but not with the limited funds and doctor / patient exposure that currently exists. I have spoken with a lot of doctors about AFREZZA and also diabetics and frankly most still know nothing or very little about it including specialists in diabetes.
|
|
|
Post by mannmade on Sept 24, 2016 19:00:58 GMT -5
Guess it depends as I am no expert in this area but must weigh constraints of any specific points of the settlement contained in an NDA (which is standard) vs what information is material to the need to know of shareholders in form of information/disclosures that triggers a need for an 8k.
|
|
|
Post by mannmade on Sept 24, 2016 15:34:01 GMT -5
Agree CCI and it's better than one dedicated to bashing Mnkd, Matt, et al...
|
|
|
Post by mannmade on Sept 24, 2016 13:48:10 GMT -5
Not to rain on anyone's parade but they would have all sorts of FTC, FCC and FDA issues to deal with. Way too many "F ing " agencies to deal with not to mention the number of lawyers....😊
I know this for a fact as I once helped to launch a pharmacy drug w an in program integration on a top rated Primetime big 3 broadcast network unscripted show.
Second even if they could overcome the above the story is too long and complex to explain.
Third why give up ownership in the company when a better platform for this type of partnership would be The Doctors, Steve Harvey, Ellen or Dr. Oz etc. pay a fee and no need to give up ownership plus ur message/story in being told on a platform with a relevant audience.
|
|
|
Post by mannmade on Sept 24, 2016 13:40:02 GMT -5
Peppy I believe you are right as that is also my understanding. Titration Paks are free w a script. The beauty of this is that essentially what is an extended sample counts as a new script and gives serious users time to find the right individual dosing/titration.
The small downside is that we won't see refills for the first Paks distributed in August until Nov most likely.
|
|
|
Post by mannmade on Sept 24, 2016 10:22:13 GMT -5
It is my understanding that most of these types of drugs take several weeks of absorption before they become effective. How would one dose work? And then people must stay on them or risk side effects for going on and off.
|
|
|
Post by mannmade on Sept 24, 2016 8:53:13 GMT -5
Yes
|
|
|
Post by mannmade on Sept 24, 2016 2:40:12 GMT -5
Yes they do but it is free.
|
|
|
Post by mannmade on Sept 23, 2016 11:23:59 GMT -5
Titration paks are free with first script.
|
|
|
Post by mannmade on Sept 22, 2016 18:38:21 GMT -5
An estimated 50 million people who suffer from diabetes lack access to insulin By Bill Berkrot
NEW YORK, Sept 21 (Reuters) - Danish drugmaker Novo Nordisk A/S pledged on Wednesday to provide insulin at steeply discounted prices in the world's least-developed nations in what it is calling its "access to insulin commitment."
The company, which produces almost half of the world's insulin, said the guarantee applied to Least Developed Countries as defined by the United Nations, other low-income nations as defined by the World Bank, and selected organizations providing relief in humanitarian situations.
"We guarantee that we will provide low-priced human insulin to ensure access to quality treatments for patients in the poorest parts of the world for many years to come," the company said in a statement.
Novo Nordisk Chief Executive Officer Lars Sorensen made the announcement while taking part in a panel discussion during the U.N. General Assembly on growing rates of non-communicable diseases among vulnerable populations.
The cost of a vial of the human insulin in 2017 under the program would be no more than $4, "which would ensure that the treatment cost per day for an individual would be anywhere between 10 and 15 cents a day," Sorensen said in an interview.
That amounts to less than 20 percent of the cost in developed countries.
Sorensen, who has been with the company for 34 years and been CEO since 2000, is stepping down at the end of the year but will work for Novo Nordisk's charitable foundation.
He pledged that the human insulin program for poor nations would be in place for "at least 10 years."
By then, Sorensen said, more modern insulin products would have become available as cheaper generics. "So I don't want to necessarily be committed to having to provide human insulin because then they might as well get the better version," he said.
More than 400 million people suffer from diabetes worldwide, while an estimated 50 million lack access to insulin, the company said. If not properly controlled, diabetes can lead to a wide range of serious health complications.
|
|
|
Post by mannmade on Sept 22, 2016 15:42:45 GMT -5
The irony is that I truly believe that AFREZZA could have been the cure for what ails their diabetes franchise. Karma is a bitch... 😊🙏
|
|
|
Post by mannmade on Sept 22, 2016 13:19:36 GMT -5
|
|
|
Post by mannmade on Sept 21, 2016 20:11:43 GMT -5
facts, I am sure Mike did his own DD and that does give me confidence that this issue will soon be addressed as it is hanging over Mnkd like a dark cloud at the moment. I think dilution imho is the only realistic solution at this point unless we get some sort of private equity deal done based on positive info not available to the public. The rest of the opportunities to raise funds or receive revenue again imo are purely wishful thinking at this point.
Sanofi not likely to settle while scripts are still low RSL payment if it does come likely to be nominal at this point Doubt we see a gift from the Mann Foundation as they have a business and other investments to support, however we might see some kind of bridge loan or equity swap as part of dilution event.
Right now it seems the best approach is to solve the money issue for the next 12 months and it will give the scripts time to grow... And then at last we may all be able to "Just breathe..."
|
|
|
Post by mannmade on Sept 21, 2016 19:57:07 GMT -5
Why Samsung Is Partnering Up with This Healthcare Company Samsung is following Apple into the wearables market by partnering with this healthcare giant. Will the partnership move the needle for either company?
Brian Feroldi (TMFTypeoh) Jun 28, 2015 at 9:43AM Consumer electronics juggernaut Samsung Electronics Co. (NASDAQOTH:SSNLF) and medical device powerhouse Medtronic PLC (NYSE:MDT) have been in the news recently after they announced a joint partnership at the American Diabetes Association 75th Scientific Sessions. The goal of the partnership is to combine each of their areas of expertise to make it easier for people with diabetes to successfully manage their disease. The companies have stated their intentions to develop a range of future solutions that will allow for patients with diabetes to have easier access to viewing their data, with the ultimate goal of fully integrating mobile and wearable devices into a complete diabetes management system.
For Samsung, this partnership will provide a foot in the door in the important health-related wearables market, as they are desperately trying to keep pace with Apple. Apple is pushing hard to be an important player in the space, as is evident from the company's recent product launches like Health Kit, Research Kit, and the Apple Watch. Establishing a direct relationship with a medical device giant like Medtronic appears to be a sound strategy for carving out a space in the market.
This deal also makes a lot of sense for Medtronic, as Samsung is a huge player in the consumer electronics market, and it's likely that a huge number of patients using Medtronic's devices already have a Samsung device. Medtronic is currently a huge player in the diabetes device market -- the company rang up more than $1.6 billion in sales in 2014 from the sale of its insulin pump and continuous glucose monitoring devices.
In a separate but related announcement, Medtronic also stated that it received FDA approval for the MiniMed Connect. The Connect consists of a small uploader device that allows for data from Medtronic's insulin pump or continuous glucose sensor to talk directly to a mobile phone. This data can then be viewed directly on the phone itself or relayed to the cloud for viewing on a variety of Internet-enabled devices. Once in the cloud the data could then be shared with a variety of healthcare providers like family members, school nurses, or physicians.
Screen Shot
IMAGE: MEDTRONIC
The Minimed Connect will go on sale for $199 this fall, and will initially be rolled out on only to iOS devices like the iPhone and iPod touch in the U.S. Medtronic did mention they plan to make the device available for Android users as well, and the company is planning on taking additional steps with Samsung mobile devices specifically, which includes developing their custom own app to optimize the experience.
If this idea sounds familiar, it should, as Medtronic's smaller but faster growing glucose sensor rival Dexcom (NASDAQ:DXCM) recently launched a similar product. The Dexcom G4 Platinum with Share went on sale earlier this year, and the device allows for Dexcom's receiver device to communicate with Apple's iOS product directly. Dexcom's system doesn't require a separate uploader like Medtronic does, and Dexcom's system is already integrated into the Apple Watch as well.
However, Medtronic's device may be more useful to providers than Dexcom's currently is, as the Connect will share insulin pump related data as well. Perhaps that extra data will be enough of an advantage to entice their users to carry yet another device on them all the time.
Will this move the needle for Medtronic? It's hard to imagine that this device's $199 price tag will come close to directly impacting Medtronic's financial statements. Diabetes Forecast magazine noted that in 2014 only about 350,000 U.S. patients currently used an insulin pump. Even if you assume that, say, 300,000 of those use Medtronic and 100% of them get the Connect, that's only $60 million or so in revenue, which is a rounding error for the company. After all, Medtronic rang up more than $17 billion in total sales in 2014, and the diabetes division contributed $1.6 billion to that number.
However, the diabetes division remains important to Medtronic, as it is one of the company's fastest growing segments, so its good to see them investing in this kind of innovation. While the Connect itself doesn't appear to be a huge money maker for the company, it could be a nice piece of technology that helps to expand Medtronic's diabetes ecosystem. Keeping users inside that ecosystem is vital to helping the diabetes division grow. Medtronic faces some serious competition on this front from the likes of Johnson & Johnson's Animas division, which recently launched a competing sensor augmented pump of their own. There are also several smaller insulin pump rivals in the space like Insulet Corporation and Tandem Diabetes Care Inc, who have been eating away market share.
This partnership seems like a great deal for both Medtronic and Samsung, and if it even slightly works to help keep patients inside the Medtronic ecosystem, it sounds like a big win for the company
|
|